TransCode Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell RNAZ and other ETFs, options, and stocks.About RNAZ
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
CEOPhilippe P. Calais
CEOPhilippe P. Calais
Employees7
Employees7
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2016
Founded2016
Employees7
Employees7
RNAZ Key Statistics
Market cap7.92M
Market cap7.92M
Price-Earnings ratio-0.04
Price-Earnings ratio-0.04
Dividend yield—
Dividend yield—
Average volume6.76K
Average volume6.76K
High today$8.88
High today$8.88
Low today$8.48
Low today$8.48
Open price$8.48
Open price$8.48
Volume3.25K
Volume3.25K
52 Week high$468.44
52 Week high$468.44
52 Week low$6.15
52 Week low$6.15
Stock Snapshot
TransCode Therapeutics(RNAZ) stock is priced at $8.88, giving the company a market capitalization of 7.92M. It carries a P/E multiple of -0.04.
On 2025-12-05, TransCode Therapeutics(RNAZ) stock traded between a low of $8.48 and a high of $8.88. Shares are currently priced at $8.88, which is +4.7% above the low and 0.0% below the high.
The TransCode Therapeutics(RNAZ)'s current trading volume is 3.25K, compared to an average daily volume of 6.76K.
During the past year, TransCode Therapeutics(RNAZ) stock moved between $6.15 at its lowest and $468.44 at its peak.
During the past year, TransCode Therapeutics(RNAZ) stock moved between $6.15 at its lowest and $468.44 at its peak.
People also own
Based on the portfolios of people who own RNAZ. This list is generated using Robinhood data, and it’s not a recommendation.